New study: Birth control pills may increase binge eating
A new study from Michigan State University found increases in binge eating when taking hormone pills in the form of oral contraceptives — but not in all women…. read more.
A new study from Michigan State University found increases in binge eating when taking hormone pills in the form of oral contraceptives — but not in all women…. read more.
A target trial emulation estimated the risks associated with glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure in early pregnancy. The findings did not indicate substantially increased risk for nonlive… read more.
People prescribed GLP-1 medications are more likely to start-and-stop than most people assume, according to a study being presented Sunday at ENDO 2026, the Endocrine Society’s annual meeting… read more.
Eli Lilly and Company, the maker of Zepbound (tirzepatide), announced results demonstrating that women with obesity or overweight who took the highest dose of Foundayo experienced significant weight… read more.
A University of California, Riverside-led study of more than 3,200 emergency department (ED) patients across the United States found that while awareness of influenza vaccination is widespread, most adults seen in… read more.
AstraZeneca’s Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve, high-risk… read more.
In people with type 2 diabetes, semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared to other anti-obesity medications, according to a… read more.
MannKind Corporation announced that the FDA has approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and… read more.
Only a small number of men who were prescribed testosterone therapy received appropriate, guideline-concordant diagnostic testing, according to a study being presented Saturday at ENDO 2026, the Endocrine Society’s annual… read more.
Novo Nordisk presented post hoc analyses from the SELECT, STEP, ESSENCE, and OASIS clinical trials at the 2026 Scientific Sessions of the American Diabetes Association (ADA), highlighting data regarding the impact… read more.
Novartis reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia (atrasentan) versus placebo in adults with IgA nephropathy (IgAN). Results were published in The… read more.
Most breast cancers are worsened by estrogens. To combat the recurrence of these cancers, clinicians treat patients with inhibitors for estrogen production, like letrozole. But many patients do not adhere to this treatment due to negative side effects. Preclinical work in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.